

# EBMT 2025 ACTIVITY SURVEY ON TRANSPLANT, CELLULAR, AND GENE THERAPY

**Submissions are now given on the online form. You will have received a link to the form from EBMT. This sheet is only to help you count the numbers.**

**Table 1a:** Report the number of adult patients receiving their 1st allogeneic and/or 1st autologous transplant in 2025 in rows 1-38. Report non 1st HCT in row 40. Light grey cells will be automatically calculated by the online form.

**Table 1b:** Report the number of paediatric patients receiving their 1st allogeneic and/or 1st autologous transplant in 2025 in rows 1-52. Report non 1st HCT in row 54. Light grey cells will be automatically calculated by the online form..

**Table 2a:** Report the number of adult patients receiving their 1st CAR-T allogeneic and autologous in 2025 in rows 1-45. Report the number of adult patients receiving their 1st Gene therapy in 2025 in rows 1-45. Report non 1st CAR-T / Gene Therapy in row 47. Light grey cells will be automatically calculated by the online form.

**Table 2b:** Report the number of paediatric patients receiving their 1st CAR-T allogeneic and autologous in 2025 in rows 1-59. Report the number of paediatric patients receiving their 1st Gene therapy in 2025 in rows 1-59. Report non 1st CAR-T / Gene Therapy in row 61. Light grey cells will be automatically calculated by the online form.

**Table 3a:** Report the number of adult patients receiving non HCT cellular therapies or cell infusions in 2025 by indication and cell type in rows 1-9.

**Table 3b:** Report the number of paediatric patients receiving non HCT cellular therapies or cell infusions in 2025 by indication and cell type in rows 1-9.

**Table 4a:** Report the number of adult patients receiving their 1st unmanipulated DLI (donor lymphocyte infusion) in 2025 in row 1.

**Table 4b:** Report the number of paediatric patients receiving their 1st unmanipulated DLI (donor lymphocyte infusion) in 2025 in row 1.

**Table 5a:** Report the number of adult patients receiving Immunosuppressive Treatments (IST) for acquired Bone Marrow Failure Syndromes in 2025 in row 1.

**Table 5b:** Report the number of paediatric patients receiving Immunosuppressive Treatments (IST) for acquired Bone Marrow Failure Syndromes in 2025 in row 1.

Table 1a: HCT		HLA-id sibling			Twin		Haplo and other HLA mismatched related donors			Unrelated			Autologous			Total Allo	Total Auto	Total HCT
		BM	PBSC	Cord	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord			
1	AML 1st CR														0	0	0	
2	AML in CR: > 1st CR														0	0	0	
3	AML not in CR														0	0	0	
4	AML therapy - related														0	0	0	
5	AML with MDS - related changes														0	0	0	
6	ALL 1st CR														0	0	0	
7	ALL non 1st CR														0	0	0	
8	CML 1st CP														0	0	0	
9	CML non 1st CP														0	0	0	
10	MDS														0	0	0	
11	MDS/MPN														0	0	0	
12	MPN														0	0	0	
13	CLL incl. PLL														0	0	0	
14	PCN - MM														0	0	0	
15	PCN - Other														0	0	0	
16	Hodgkin lymphoma														0	0	0	
17	DLBCL NHL - all types														0	0	0	
18	Mantle cell lymphoma														0	0	0	
19	Follicular lymphoma														0	0	0	
20	Primary mediastinal large B-cell lymphoma														0	0	0	
21	Other B-cell NHL														0	0	0	
22	T-cell NHL														0	0	0	
23	Solid Tumours - Neuroblastoma														0	0	0	
24	Solid Tumours - Soft tissue														0	0	0	
25	Solid Tumours - Ewing sarcoma														0	0	0	

26	Solid Tumours - Germ cell tumour															0	0	0
27	Other solid tumours															0	0	0
28	Acquired BMF - AA*															0	0	0
29	Acquired BMF - PNH-AA*															0	0	0
30	Thalassaemia															0	0	0
31	Sickle cell disease															0	0	0
32	Inborn Errors of Immunity															0	0	0
33	Inborn Errors of Metabolism															0	0	0
34	Autoimmune Diseases - MS															0	0	0
35	Autoimmune Diseases - SSC															0	0	0
36	Autoimmune Diseases - SLE															0	0	0
37	Autoimmune Diseases - Other															0	0	0
38	Other rare disorders (incl. Histiocytosis)															0	0	0
39	<b>Total 1st HCT (row 1-38)</b>	<b>0</b>																
40	<b>Additional non 1st HCT</b>															0	0	0
41	<b>Total all HCT</b>	<b>0</b>																

HCT totals

AA\* includes moderate, severe and very severe cases

Table 1b: HCT		HLA-id sibling			Twin		Haplo and other HLA mismatched related donors			Unrelated			Autologous			Total Allo	Total Auto	Total HCT
		BM	PBSC	Cord	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord			
1	AML 1st CR														0	0	0	
2	AML in CR: > 1st CR														0	0	0	
3	AML not in CR														0	0	0	
4	AML therapy - related														0	0	0	
5	AML with MDS - related changes														0	0	0	
6	ALL 1st CR														0	0	0	
7	ALL non 1st CR														0	0	0	
8	CML 1st CP														0	0	0	
9	CML non 1st CP														0	0	0	
10	MDS														0	0	0	
11	MPN - JMML														0	0	0	
12	MPN - Other (excl. JMML)														0	0	0	
13	Hodgkin lymphoma														0	0	0	
14	DLBCL NHL - all types														0	0	0	
15	Burkitt lymphoma														0	0	0	
16	Primary mediastinal large B-cell lymphoma														0	0	0	
17	Other B-cell NHL														0	0	0	
18	T-cell NHL														0	0	0	
19	Solid Tumours - Neuroblastoma														0	0	0	
20	Solid Tumours - Soft tissue														0	0	0	
21	Solid Tumours - Ewing sarcoma														0	0	0	
22	Solid Tumours - Germ cell tumour														0	0	0	
23	Solid Tumours - Nephroblastoma														0	0	0	



27	Solid Tumours - Germ cell tumour							
28	Other solid tumours							
29	Acquired BMF - AA*							
30	Acquired BMF - PNH-AA*							
31	Thalassaemia							
32	Sickle cell disease							
33	Inborn Errors of Immunity							
34	Inborn Errors of Metabolism							
35	Autoimmune Diseases - MS							
36	Autoimmune Diseases - SSC							
37	Autoimmune Diseases - SLE							
38	Autoimmune Diseases - Myositis							
39	Autoimmune Diseases - Myasthenia Gravis							
40	Autoimmune Diseases - Other							
41	Other rare disorders (incl. Histiocytosis)							
42	GVHD							
43	Graft Failure/Enhancement							
44	Infection							
45	Other complications							
46	<b>Total 1st CAR-T / Gene Therapy (row 1-45)</b>	<b>0</b>						
47	<b>Additional non 1st CAR-T / Gene Therapy</b>							
48	<b>Total all CAR-T / Gene Therapy</b>	<b>0</b>						

AA\* includes moderate, severe and very severe cases

How many CAR-T ( autologous and allogeneic) and Autologous HSC Gene Therapies reported in your centre in 2025 were academic?	
--	--

Table 2b: Gene Therapies		CAR-T		Other genetically modified T-cells		Autologous HSC Gene therapies	Other Gene therapies	
		AUTO	ALLO	AUTO	ALLO	AUTO	AUTO	ALLO
1	AML 1st CR							
2	AML in CR: > 1st CR							
3	AML not in CR							
4	AML therapy - related							
5	AML with MDS - related changes							
6	ALL 1st CR							
7	ALL relapse post-HCT							
8	ALL non 1st CR							
9	CML 1st CP							
10	CML non 1st CP							
11	MDS							
12	MPN - JMML							
13	MPN - Other (excl. JMML)							
14	Hodgkin Lymphoma							
15	DLBCL NHL - all types							
16	Burkitt Lymphoma							
17	Primary mediastinal large B-cell lymphoma							
18	Other B-cell NHL							
19	T-cell NHL							
20	Solid Tumours - Neuroblastoma							
21	Solid Tumours - Soft tissue							
22	Solid Tumours - Ewing sarcoma							
23	Solid Tumours - Germ cell tumour							
24	Solid Tumours. Nephroblastoma							
25	Other solid tumours							
26	Acquired BMF - AA*							
27	Acquired BMF - PNH-AA*							
28	Acquired BMF - classical PNH							
29	Acquired BMF - Other							
30	Constitutional BMF - DBA							
31	Constitutional BMF - Fanconi Anemia							
32	Constitutional BMF - SDS							
	Constitutional BMF - Dyskeratosis congenita and other							
33	TBD							
34	Constitutional BMF - SAMD9/D9L Syndromes							
35	Constitutional BMF - Other							
36	Thalassaemia							
37	Sickle cell disease							
38	Inborn Errors of Immunity - SCID							
39	Inborn Errors of Immunity - WAS							

40	Inborn Errors of Immunity - CGD							
41	Inborn Errors of Immunity - DADA2							
42	Inborn Errors of Immunity - Primary HLH							
43	Inborn Errors of Immunity - Other (including acquired HLH)							
44	Inborn Errors of Metabolism - X-ALD							
45	Inborn Errors of Metabolism - MPS I							
46	Inborn Errors of Metabolism - MLD							
47	Inborn Errors of Metabolism - Other							
48	Autoimmune Diseases - MS							
49	Autoimmune Diseases - SSC							
50	Autoimmune Diseases - SLE							
51	Autoimmune Diseases - JIA							
52	Autoimmune Diseases - Myositis							
53	Autoimmune Diseases - Myasthenia Gravis							
54	Autoimmune Diseases - other							
55	Other rare disorders (incl. Histiocytosis)							
56	GVHD							
57	Graft Failure/Enhancement							
58	Infection							
59	Other complications							
60	<b>Total 1st CAR-T / Gene Therapy (row 1-59)</b>	<b>0</b>						
61	<b>Additional non 1st CAR-T / Gene Therapy</b>							
62	<b>Total all CAR-T / Gene Therapy</b>	<b>0</b>						

AA\* includes moderate, severe and very severe cases

How many CAR-T ( autologous and allogeneic) and Autologous HSC Gene Therapies reported in your centre in 2025 were academic?

Table 3a: Number of adult patients receiving Other Cellular Therapies (excluding HCT, gene therapy and DLI)		Selected/expanded T cells or CIK		Regulatory T cells (TREGS)		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Other therapies (incl. boosts)	
		Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto
1	GvHD														
2	Graft enhancement/failure														
3	Autoimmune disease														
4	Genetic disease														
5	Infection														
6	Malignancy - ALL														
7	Malignancy - Lymphoma														
8	Malignancy - Myeloma														
9	Any other indication														

Table 3b: Number of paediatric patients receiving Other Cellular Therapies (excluding HCT, gene therapy and DLI)		Selected/expanded T cells or CIK		Regulatory T cells (TREGS)		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Other therapies (incl. boosts)	
		Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto
1	GvHD														
2	Graft enhancement/failure														
3	Autoimmune disease														
4	Genetic disease														
5	Infection														
6	Malignancy - ALL														
7	Malignancy - Lymphoma														
8	Malignancy - Myeloma														
9	Any other indication														

1	<b>Table 4a:</b> Total Number of adult patients receiving <b>unmanipulated</b> DLI in 2025:		For graft enhancement/failure:		For residual disease:		For relapse:		Per protocol:	
---	---	--	--------------------------------	--	-----------------------	--	--------------	--	---------------	--

1	<b>Table 4b:</b> Total Number of paediatric patients receiving <b>unmanipulated</b> DLI in 2025:		For graft enhancement/failure:		For residual disease:		For relapse:		Per protocol:	
---	--	--	--------------------------------	--	-----------------------	--	--------------	--	---------------	--

1	<b>Table 5a:</b> Total Number of adult patients receiving Immunosuppressive Treatments (IST) for <b>Acquired Bone Marrow Failure Syndromes</b> in 2025:		For Aplastic Anaemia (AA):		For other Bone Marrow Failure Syndromes:	
---	---	--	----------------------------	--	--	--

1	<b>Table 5b:</b> Total Number of paediatric patients receiving Immunosuppressive Treatments (IST) for <b>Acquired Bone Marrow Failure Syndromes</b> in 2025:		For Aplastic Anaemia (AA):		For other Bone Marrow Failure Syndromes:	
---	--	--	----------------------------	--	--	--